KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Change in Cash (2016 - 2025)

Elevance Health (ELV) has disclosed Change in Cash for 17 consecutive years, with $778.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 66.24% to $778.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 34.19% decrease, with the full-year FY2025 number at $1.2 billion, down 34.19% from a year prior.
  • Change in Cash was $778.0 million for Q4 2025 at Elevance Health, up from $153.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $3.6 billion in Q1 2021 to a low of -$4.1 billion in Q2 2021.
  • A 5-year average of $432.1 million and a median of $295.0 million in 2022 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 695.61% in 2021, then soared 941.38% in 2022.
  • Elevance Health's Change in Cash stood at -$610.0 million in 2021, then tumbled by 143.44% to -$1.5 billion in 2022, then surged by 162.49% to $928.0 million in 2023, then tumbled by 49.57% to $468.0 million in 2024, then soared by 66.24% to $778.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Change in Cash are $778.0 million (Q4 2025), $153.0 million (Q3 2025), and $1.1 billion (Q2 2025).